Protein C News and Research

RSS

Protein bits produced by unusual "reading" of HIV genome can induce immune responses

Two new studies showing that protein bits produced by unusual "reading" of the HIV genome can induce immune responses will appear online in the Journal of Experimental Medicine on Jan. 11 (www.jem.org).

12 Jan 2010

Millipore introduces new Viresolve Pro+ Solution

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market.

12 Jan 2010

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Inhibitex, Inc. today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults.

12 Jan 2010

AvidBiotics and Ecolab to develop new technology that reduces food pathogens in meat products

AvidBiotics Corp. and Ecolab Inc. today announced an agreement under which they will work to develop a new technology to dramatically reduce the presence of the dangerous pathogen E. coli O157:H7 in red meat products.

12 Jan 2010

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

A growth factor that is a common target of cancer drugs also plays an important role in the heart's response to stress, researchers at The University of Texas M. D. Anderson Cancer Center report online this week in the Journal of Clinical Investigation.

12 Jan 2010

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

The cardiovascular risk that is associated with proteinuria, or high levels of protein in the urine, a common test used by doctors as an indicator of increased risk for progressive kidney disease, heart attack and stroke, has race-dependent effects, according to a new study by researchers at Wake Forest University School of Medicine.

12 Jan 2010

University of Haifa receives grant to investigate role of protein expression in memory formation

Prof. Kobi Rosenblum, Head of the Department of Neurobiology and Ethology at the University of Haifa, has been awarded a -1.6 million grant from DIP, a German-Israeli Project Cooperation, over a five-year period. This grant will fund Prof. Rosenblum's international research of the role of protein expression in memory formation and stability.

12 Jan 2010

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Trubion Pharmaceuticals, Inc. today announced that its collaboration partner, Pfizer, has initiated a Phase 2 clinical trial of SBI-087 (PF-05230895) for the treatment of rheumatoid arthritis (RA). SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic directed against the CD20 antigen. SBI-087 is also being evaluated in Phase 1 clinical trials for RA and systemic lupus erythematosus (SLE).

12 Jan 2010

Cancer drug may provide an effective secondary treatment for gut tumor

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh Cancer Institute (UPCI). The findings, based on experiments using cell cultures, were published in the Jan. 1 issue of Cancer Research.

12 Jan 2010

New therapeutic treatment may provide a potential alternative to bone grafting operation

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

NIH renews grant to continue cell growth regulation research

The new year began on a high note for Alan Leonard and Julia Grimwade, professors of biological sciences at Florida Institute of Technology, when they learned their National Institutes of Health grant, which they have held for the last 11 years, had been renewed for four more years. The competitive renewal brings them $1,024, 944 to continue their research into the regulation of cell growth and division.

11 Jan 2010

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

11 Jan 2010

New technique may help researchers to test amyloid hypothesis in AD development

Current Alzheimer's disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Research into "chemical chaperone" may lead to new treatments for heart attacks

Researchers at the Indiana University and Stanford University schools of medicine have determined how a "chemical chaperone" does its job in the body, which could lead to a new class of drugs to help reduce the muscle damage caused by heart attacks.

10 Jan 2010

Gene therapy may help correct molecular flaws that cause brain disease

Neuroscientists have forged an unlikely molecular union as part of their fight against diseases of the brain and nervous system.

9 Jan 2010

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Los Alamos National Laboratory (www.lanl.gov) has identified the Top 10 Laboratory science stories of 2009 based on global viewership of online media content and major programmatic milestones.

9 Jan 2010

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has discovered a key mechanism related to the systemic delivery of RNAi therapeutics using lipid nanoparticles (LNPs). The new pre-clinical research was presented at the “Advances in Biopharmaceuticals” Keystone Symposium held January 8-13, 2010 in Midway, Utah, and was performed in collaboration with scientists at the Max Planck Institute of Molecular Cell Biology and Genetics.

9 Jan 2010

Scientific societies to hold Experimental Biology 2010 meeting

Six scientific societies announced they will hold their annual meeting, Experimental Biology (EB 2010; www.experimentalbiology.org), April 24-28, 2010 in Anaheim, CA. The societies are the American Association of Anatomists (AAA), American Physiological Society (APS), American Society for Biochemistry and Molecular Biology (ASBMB), American Society for Investigative Pathology (ASIP), American Society for Nutrition (ASN) and American Society for Pharmacology and Experimental Therapeutics (ASPET).

9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Protein C News and Research

Protein bits produced by unusual "reading" of HIV genome can induce immune responses

Millipore introduces new Viresolve Pro+ Solution

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

AvidBiotics and Ecolab to develop new technology that reduces food pathogens in meat products

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

University of Haifa receives grant to investigate role of protein expression in memory formation

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Cancer drug may provide an effective secondary treatment for gut tumor

New therapeutic treatment may provide a potential alternative to bone grafting operation

NIH renews grant to continue cell growth regulation research

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

New technique may help researchers to test amyloid hypothesis in AD development

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Research into "chemical chaperone" may lead to new treatments for heart attacks

Gene therapy may help correct molecular flaws that cause brain disease

Los Alamos National Laboratory identifies 'Top 10 Laboratory science stories of 2009'

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Scientific societies to hold Experimental Biology 2010 meeting

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News